JND3229

Product Name: JND3229
CAS No.: 2260886-64-2
Chemical Name: JND3229
Synonyms: JND3229;JND3229 (JND-3229;JND3229, 10 mM in DMSO;JND3229;JND-3229;JND 3229;N-(trans-4-(3-(2-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)cyclohexyl)propionamide;N-[(1r,4r)-4-[3-(2-chlorophenyl)-7-{[3-methyl-4-(4-methylpiperazin-1-yl)phenyl]amino}-2-oxo-1H,2H,3H,4H-[1,3]diazino[4,5-d]pyrimidin-1-yl]cyclohexyl]propanamide;Propanamide, N-[trans-4-[3-(2-chlorophenyl)-3,4-dihydro-7-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]cyclohexyl]-
CBNumber: CB24844930
Molecular Formula: C33H41ClN8O2
Formula Weight: 617.18
MOL File: 2260886-64-2.mol

More

Less

JND3229 Property

Density: 1.34±0.1 g/cm3(Predicted)
storage temp.: 2-8°C
solubility: DMSO : 12.5 mg/mL (20.25 mM; Need ultrasonic)
pka: 16.01±0.40(Predicted)
form: Solid
color: White to light yellow

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

N-Bromosuccinimide Price

ChemScene

Product number: CS-0078820
Product name: JND3229
Purity: 99.38%
Packaging: 5mg
Price: $395
Updated: 2021/12/16

ChemScene

Product number: CS-0078820
Product name: JND3229
Purity: 99.38%
Packaging: 10mg
Price: $605
Updated: 2021/12/16

Biorbyt Ltd

Product number: orb573230
Product name: JND3229
Purity: >98%
Packaging: 5mg
Price: $765
Updated: 2021/12/16

Biorbyt Ltd

Product number: orb573230
Product name: JND3229
Purity: >98%
Packaging: 10mg
Price: $1283.5
Updated: 2021/12/16

ChemScene

Product number: CS-0078820
Product name: JND3229
Purity: 99.38%
Packaging: 50mg
Price: $1850
Updated: 2021/12/16

More

Less

JND3229 Chemical Properties,Usage,Production

Uses

JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma[1].

in vivo

JND3229 (10 mg/kg; i.p.; twice daily for 10 days) exhibits an obvious suppression of tumor growth, and shows target inhibition in vivo^[1].

Animal Model:	BALB/c mice (bearing established BaF3-EGFR19D/T790M/C797S mouse xenograft tumors model)^[1].
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; twice daily for 10 days.
Result:	Caused an obvious suppression of tumor growth with a Tumor Growth Inhibition (TGI) value of 42.2%. Showed well tolerance without obvious body weight loss or other obvious toxic sign in the treated animals. Significantly decreased the level of phosphorylated EGFR (p-EGFR) tin the tumor tissues.

References

[1] Lu X, et al. Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Med Chem Lett. 2018 Oct 8;9(11):1123-1127. DOI:10.1021/acsmedchemlett.8b00373

JND3229 Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

JND3229 Suppliers

China 38 United States 3 Global 41

TargetMol Chemicals Inc.

Tel: +1-781-999-5354; +17819995354
Email: marketing@targetmol.com
Country: United States
ProdList: 32435
Advantage: 58

Aladdin Scientific

Tel
Email: tp@aladdinsci.com
Country: United States
ProdList: 52923
Advantage: 58

MedChemExpress

Tel: --
Fax: --
Email: sales@medchemexpress.com
Country: United States
ProdList: 6398
Advantage: 58

2260886-64-2, JND3229Related Search:

JND3229

JND3229 (JND-3229

JND3229;JND-3229;JND 3229

Propanamide, N-[trans-4-[3-(2-chlorophenyl)-3,4-dihydro-7-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]cyclohexyl]-

N-(trans-4-(3-(2-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)cyclohexyl)propionamide

N-[(1r,4r)-4-[3-(2-chlorophenyl)-7-{[3-methyl-4-(4-methylpiperazin-1-yl)phenyl]amino}-2-oxo-1H,2H,3H,4H-[1,3]diazino[4,5-d]pyrimidin-1-yl]cyclohexyl]propanamide

JND3229, 10 mM in DMSO

2260886-64-2

C33H41ClN8O2